Stephen B. Hanauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen B. Hanauer has a total of 405 co-authors. Here are the top co-authors by number of shared publications:
- Silvio Danese
Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
9 shared publications - Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
8 shared publications - Stefan Schreiber
Institute of Clinical Molecular Biology, Kiel University
8 shared publications - Bruce E. Sands
Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York New York USA
7 shared publications - Dong-Hyeon Kim
Global Medical Division, Celltrion Inc., Incheon, Republic of Korea
4 shared publications - Laurent Peyrin-Biroulet
Northwestern Medicine, Digestive Health Institute, Chicago, IL 60611, USA
4 shared publications
Latest Publications
- 29 October 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1) , 37
The Importance of Early (Effective) Interventions in Crohn’s Disease: Current Concepts and Emerging Evidence
- 29 October 2026
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 28 (1) , 37
The Importance of Early (Effective) Interventions in Crohn’s Disease: Current Concepts and Emerging Evidence
- Open Access
- 31 July 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e92202
End User Needs and Perspectives for a Digital Opioid Safety Tool in Adolescents and Young Adults With Inflammatory Bowel Disease: A Qualitative Human-Centered Design Study
Background: Chronic opioid use, a key predictor of opioid overdose, is common among adolescents and young adults (AYA) with inflammatory bowel diseases (IBD), underscoring a need for tailored interventions to monitor risk for opioid-related harm. Prior research highlights the need to engage both AYA patients with IBD and IBD-focused clinicians in the development of pain management and opioid safety interventions. Human-centered design offers a promising approach to address this gap by directly engaging patients and clinicians in cocreating solutions. Objective: We aimed to explore and identify AYA patient and clinician perspectives to inform the design and development of a digital opioid safety tool. Methods: Using convenience sampling, we conducted semistructured interviews with AYA patients with IBD and IBD-focused clinicians (gastroenterologists, surgeons, and nurses) in July-August 2023 in person or by video-based conferencing. Interviews explored patient experiences with pain management, opioid use, and transitions to adult care, as well as clinician experiences in monitoring pain and prescribing opioids. A co-design workshop, following the interviews, brought patient and clinician participants together to reflect as a group on the unique challenges of managing pain in IBD care, and consider potential creative solutions to enhance pain management safety. The workshop was facilitated in person in September 2023 and included 7 patients and 8 clinicians who previously participated in individual interviews. Data were audio recorded, transcribed, and thematically analyzed using an inductive approach to identify themes. Results: Twenty participants (7 AYA patients and 13 clinicians) contributed to the study. Thematic analysis generated three domains of needs that a digital opioid safety tool should address: (1) Intersecting Needs (ie, relevant at the patient and clinician and/or health system levels), (2) Patient-Level Needs (ie, relevant at the patient level only), and (3) Clinician- and/or Health System–Level Needs (ie, relevant at the clinician and/or health system levels only). Intersecting needs included integrating opioid safety interventions into multidisciplinary chronic care, supporting AYA transitions to independence, and acknowledging individual patient differences. Patient-level needs included assessing lived experiences of pain routinely, setting clear expectations about pain management, and connecting patients with safe nonopioid alternatives. Clinician- and/or health system–level needs included accounting for pain management received outside the IBD clinic; addressing gaps in information, education, and resources regarding opioid risk or pain management; and coordinating safety efforts across clinical teams. Conclusions: Incorporating these insights into the development of a digital opioid safety tool may enhance alignment between patient and clinician expectations on pain management and opioid use. This study underscores the value of human-centered design in developing digital opioid safety tools that are practical, patient-focused, and effectively integrated into clinical workflows. Findings may guide future intervention design, prototyping, and testing with continued engagement of AYA patients with IBD and clinicians.
- 31 July 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e92202
Open AccessEnd User Needs and Perspectives for a Digital Opioid Safety Tool in Adolescents and Young Adults With Inflammatory Bowel Disease: A Qualitative Human-Centered Design Study
Background: Chronic opioid use, a key predictor of opioid overdose, is common among adolescents and young adults (AYA) with inflammatory bowel diseases (IBD), underscoring a need for tailored interventions to monitor risk for opioid-related harm. Prior research highlights the need to engage both AYA patients with IBD and IBD-focused clinicians in the development of pain management and opioid safety interventions. Human-centered design offers a promising approach to address this gap by directly engaging patients and clinicians in cocreating solutions. Objective: We aimed to explore and identify AYA patient and clinician perspectives to inform the design and development of a digital opioid safety tool. Methods: Using convenience sampling, we conducted semistructured interviews with AYA patients with IBD and IBD-focused clinicians (gastroenterologists, surgeons, and nurses) in July-August 2023 in person or by video-based conferencing. Interviews explored patient experiences with pain management, opioid use, and transitions to adult care, as well as clinician experiences in monitoring pain and prescribing opioids. A co-design workshop, following the interviews, brought patient and clinician participants together to reflect as a group on the unique challenges of managing pain in IBD care, and consider potential creative solutions to enhance pain management safety. The workshop was facilitated in person in September 2023 and included 7 patients and 8 clinicians who previously participated in individual interviews. Data were audio recorded, transcribed, and thematically analyzed using an inductive approach to identify themes. Results: Twenty participants (7 AYA patients and 13 clinicians) contributed to the study. Thematic analysis generated three domains of needs that a digital opioid safety tool should address: (1) Intersecting Needs (ie, relevant at the patient and clinician and/or health system levels), (2) Patient-Level Needs (ie, relevant at the patient level only), and (3) Clinician- and/or Health System–Level Needs (ie, relevant at the clinician and/or health system levels only). Intersecting needs included integrating opioid safety interventions into multidisciplinary chronic care, supporting AYA transitions to independence, and acknowledging individual patient differences. Patient-level needs included assessing lived experiences of pain routinely, setting clear expectations about pain management, and connecting patients with safe nonopioid alternatives. Clinician- and/or health system–level needs included accounting for pain management received outside the IBD clinic; addressing gaps in information, education, and resources regarding opioid risk or pain management; and coordinating safety efforts across clinical teams. Conclusions: Incorporating these insights into the development of a digital opioid safety tool may enhance alignment between patient and clinician expectations on pain management and opioid use. This study underscores the value of human-centered design in developing digital opioid safety tools that are practical, patient-focused, and effectively integrated into clinical workflows. Findings may guide future intervention design, prototyping, and testing with continued engagement of AYA patients with IBD and clinicians.
- Open Access
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn’s disease: post hoc results from the phase 3b SEQUENCE trial
Background: This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) versus ustekinumab (UST) in patients with moderate to severe Crohn’s disease (CD) with prior inadequate response or intolerance to ≥ 1 anti-tumor necrosis factor (TNF) therapy. Methods: SEQUENCE (NCT04524611) was an open-label, multicenter, randomized, efficacy assessment-blinded study. Patients were randomized 1:1 to receive RZB (intravenous [IV] 600 mg induction dose at weeks 0, 4, and 8, then a subcutaneous [SC] 360 mg maintenance dose every 8 weeks [Q8w] starting at week 12) or UST (single weight-based IV induction dose, then a SC 90 mg maintenance dose Q8w starting at week 8) up to week 48. Patients tapered corticosteroids beginning at week 2. Achievement of clinical, endoscopic, and quality of life outcomes without concomitant use of steroids (“corticosteroid-free”) and safety were assessed. Results: In patients taking corticosteroids at baseline, response rate differences by the week 24 and 48 timepoints with RZB versus UST were 10.5% and 25.4% (P ≤ .01) for corticosteroid-free clinical remission per CD activity index and 20.4% (P ≤ .001) and 29.2% (P ≤ .01) per stool frequency/abdominal pain score, and 23.0% and 20.2% (both P ≤ .01) for corticosteroid-free endoscopic remission. Similar results were also observed for additional corticosteroid-free endpoints, including endoscopic, composite (clinical + endoscopic), and quality of life outcomes. Numerically higher exposure-adjusted event rates of serious infections and hypersensitivity with RZB and UST were observed with corticosteroid use. Conclusion: In patients with CD refractory to anti-TNF therapy, higher rates of corticosteroid-free clinical, endoscopic, and quality of life outcomes were achieved with RZB versus UST. Both treatments were well-tolerated. Clinical trial registration number: NCT04524611
- 7 July 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (7)
Open AccessCorticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn’s disease: post hoc results from the phase 3b SEQUENCE trial
Background: This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) versus ustekinumab (UST) in patients with moderate to severe Crohn’s disease (CD) with prior inadequate response or intolerance to ≥ 1 anti-tumor necrosis factor (TNF) therapy. Methods: SEQUENCE (NCT04524611) was an open-label, multicenter, randomized, efficacy assessment-blinded study. Patients were randomized 1:1 to receive RZB (intravenous [IV] 600 mg induction dose at weeks 0, 4, and 8, then a subcutaneous [SC] 360 mg maintenance dose every 8 weeks [Q8w] starting at week 12) or UST (single weight-based IV induction dose, then a SC 90 mg maintenance dose Q8w starting at week 8) up to week 48. Patients tapered corticosteroids beginning at week 2. Achievement of clinical, endoscopic, and quality of life outcomes without concomitant use of steroids (“corticosteroid-free”) and safety were assessed. Results: In patients taking corticosteroids at baseline, response rate differences by the week 24 and 48 timepoints with RZB versus UST were 10.5% and 25.4% (P ≤ .01) for corticosteroid-free clinical remission per CD activity index and 20.4% (P ≤ .001) and 29.2% (P ≤ .01) per stool frequency/abdominal pain score, and 23.0% and 20.2% (both P ≤ .01) for corticosteroid-free endoscopic remission. Similar results were also observed for additional corticosteroid-free endpoints, including endoscopic, composite (clinical + endoscopic), and quality of life outcomes. Numerically higher exposure-adjusted event rates of serious infections and hypersensitivity with RZB and UST were observed with corticosteroid use. Conclusion: In patients with CD refractory to anti-TNF therapy, higher rates of corticosteroid-free clinical, endoscopic, and quality of life outcomes were achieved with RZB versus UST. Both treatments were well-tolerated. Clinical trial registration number: NCT04524611
- Open Access
- 13 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag053
The Association Between 6-Thioguanine Nucleotide Levels, Adalimumab Exposure, Immune Response, and Drug Clearance
Background: Thiopurines are associated with improved infliximab pharmacokinetics (PK), but their impact on adalimumab PK and immunogenicity is not well defined. This study examined associations between 6-thioguanine (6-TGN) levels and antibodies to adalimumab (ATA), adalimumab drug levels (ADL), and adalimumab clearance (CL). Methods: Using a large clinical laboratory database, we included adults with Crohn’s disease or ulcerative colitis treated with thiopurines and adalimumab who had RBC 6-TGN and adalimumab concentrations measured within 30 days. ATA, ADL, and CL were assessed using drug-tolerant assays and nonlinear mixed-effects modeling. A 6-TGN threshold of ≥ 125 pmol/8 × 108 RBCs was used. Logistic regression was performed to calculate odds ratios (ORs). Results: We analyzed 1,194 specimens from 1,100 patients; ATA positivity was 3.7%. Compared with 6-TGN ≥125 pmol/8 × 108 RBCs, lower 6-TGN was associated with higher odds of ATA formation (>1.7 U/mL; OR = 2.55), lower odds of ADL ≥10 µg/mL (OR = 0.58), and lower odds of low CL (< 0.318 L/day; OR = 0.55). Compared with every-other-week dosing, weekly dosing produced higher ADL (13.1 vs 8.9 µg/mL; p < 0.01) but also higher CL (0.425 vs 0.302 L/day; p < 0.01). Within each dosing interval, higher 6-TGN levels were associated with lower prevalence of ATA (p < 0.05) and a higher chance of achieving ADL ≥10 µg/mL (p < 0.01) and CL < 0.318 L/day (p < 0.01). Conclusion: Higher 6-TGN levels are associated with reduced immunogenicity, higher adalimumab drug levels, and lower clearance. Thiopurine may enhance adalimumab PK and support more favorable therapeutic response.
- 13 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag053
Open AccessThe Association Between 6-Thioguanine Nucleotide Levels, Adalimumab Exposure, Immune Response, and Drug Clearance
Background: Thiopurines are associated with improved infliximab pharmacokinetics (PK), but their impact on adalimumab PK and immunogenicity is not well defined. This study examined associations between 6-thioguanine (6-TGN) levels and antibodies to adalimumab (ATA), adalimumab drug levels (ADL), and adalimumab clearance (CL). Methods: Using a large clinical laboratory database, we included adults with Crohn’s disease or ulcerative colitis treated with thiopurines and adalimumab who had RBC 6-TGN and adalimumab concentrations measured within 30 days. ATA, ADL, and CL were assessed using drug-tolerant assays and nonlinear mixed-effects modeling. A 6-TGN threshold of ≥ 125 pmol/8 × 108 RBCs was used. Logistic regression was performed to calculate odds ratios (ORs). Results: We analyzed 1,194 specimens from 1,100 patients; ATA positivity was 3.7%. Compared with 6-TGN ≥125 pmol/8 × 108 RBCs, lower 6-TGN was associated with higher odds of ATA formation (>1.7 U/mL; OR = 2.55), lower odds of ADL ≥10 µg/mL (OR = 0.58), and lower odds of low CL (< 0.318 L/day; OR = 0.55). Compared with every-other-week dosing, weekly dosing produced higher ADL (13.1 vs 8.9 µg/mL; p < 0.01) but also higher CL (0.425 vs 0.302 L/day; p < 0.01). Within each dosing interval, higher 6-TGN levels were associated with lower prevalence of ATA (p < 0.05) and a higher chance of achieving ADL ≥10 µg/mL (p < 0.01) and CL < 0.318 L/day (p < 0.01). Conclusion: Higher 6-TGN levels are associated with reduced immunogenicity, higher adalimumab drug levels, and lower clearance. Thiopurine may enhance adalimumab PK and support more favorable therapeutic response.
- Open Access
- 15 April 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (3) , e70205
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials
Background and Aims: LIBERTY‐CD and LIBERTY‐UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti‐drug antibodies (ADAs) on clinical outcomes. Methods: Patients randomized to IFX SC maintenance treatment in the LIBERTY trials were included (CD, n = 231; UC, n = 294). ADAs were tested using a highly sensitive, drug‐tolerant assay. Patients were grouped by ADA occurrence and titer and evaluated for outcomes up to Week (W) 54. Results: Among patients with CD and UC, 150 (64.9%) and 187 (63.6%) were ADA‐positive, respectively. No statistically significant differences were observed between the ADA‐positive and ADA‐negative groups in W54 efficacy (CD: clinical remission, 69.5% [95% confidence interval: 61.6–77.5] vs. 79.7% [70.2–89.2], p = 0.134; endoscopic response, 57.5% [48.9–66.1] vs. 65.2% [54.0–76.5], p = 0.359; UC: clinical remission, 49.1% [41.3–56.8] vs. 57.0% [46.5–67.4], p = 0.284), drug persistence (CD: 84.7% [79.1–90.6] vs. 85.2% [77.8–93.3]; UC: 84.5% [79.5–89.8] vs. 77.6% [70.1–85.9]), and safety (patients with ≥ 1 treatment‐emergent adverse event; CD: 71.2% [64.0–78.3] vs. 74.4% [64.9–83.8]; UC: 69.5% [62.9–76.0] vs. 64.2% [55.0–73.3]), despite lower drug concentrations in ADA‐positive patients at W54 (CD: 10.6 μg/mL [9.1–12.2] vs. 17.9 μg/mL [15.8–20.1]; UC: 12.2 μg/mL [10.8–13.5] vs. 21.0 μg/mL [18.4–23.6]). No significant relationship between ADA titer and efficacy or persistence was noted. Conclusions: Although ADAs affected drug levels, no significant differences by ADA occurrence were observed in W54 efficacy or safety among patients receiving IFX SC maintenance treatment. While high ADA titers were associated with lower drug levels, effectiveness was not diminished within 1 year. Trial Registration: ClinicalTrials.gov identifiers NCT03945019 (LIBERTY‐CD) and NCT04205643 (LIBERTY‐UC)
- 15 April 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (3) , e70205
Open AccessImpact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials
Background and Aims: LIBERTY‐CD and LIBERTY‐UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti‐drug antibodies (ADAs) on clinical outcomes. Methods: Patients randomized to IFX SC maintenance treatment in the LIBERTY trials were included (CD, n = 231; UC, n = 294). ADAs were tested using a highly sensitive, drug‐tolerant assay. Patients were grouped by ADA occurrence and titer and evaluated for outcomes up to Week (W) 54. Results: Among patients with CD and UC, 150 (64.9%) and 187 (63.6%) were ADA‐positive, respectively. No statistically significant differences were observed between the ADA‐positive and ADA‐negative groups in W54 efficacy (CD: clinical remission, 69.5% [95% confidence interval: 61.6–77.5] vs. 79.7% [70.2–89.2], p = 0.134; endoscopic response, 57.5% [48.9–66.1] vs. 65.2% [54.0–76.5], p = 0.359; UC: clinical remission, 49.1% [41.3–56.8] vs. 57.0% [46.5–67.4], p = 0.284), drug persistence (CD: 84.7% [79.1–90.6] vs. 85.2% [77.8–93.3]; UC: 84.5% [79.5–89.8] vs. 77.6% [70.1–85.9]), and safety (patients with ≥ 1 treatment‐emergent adverse event; CD: 71.2% [64.0–78.3] vs. 74.4% [64.9–83.8]; UC: 69.5% [62.9–76.0] vs. 64.2% [55.0–73.3]), despite lower drug concentrations in ADA‐positive patients at W54 (CD: 10.6 μg/mL [9.1–12.2] vs. 17.9 μg/mL [15.8–20.1]; UC: 12.2 μg/mL [10.8–13.5] vs. 21.0 μg/mL [18.4–23.6]). No significant relationship between ADA titer and efficacy or persistence was noted. Conclusions: Although ADAs affected drug levels, no significant differences by ADA occurrence were observed in W54 efficacy or safety among patients receiving IFX SC maintenance treatment. While high ADA titers were associated with lower drug levels, effectiveness was not diminished within 1 year. Trial Registration: ClinicalTrials.gov identifiers NCT03945019 (LIBERTY‐CD) and NCT04205643 (LIBERTY‐UC)
- 2 April 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
Reply
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (7) , 1235-1247
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials
Background: Rapidity of onset of efficacy following dose escalation of subcutaneous infliximab after loss of response remains unclear in Crohn’s disease (CD) and ulcerative colitis (UC). This post hoc analysis of the LIBERTY-CD and LIBERTY-UC trials evaluated time to response recovery following dose escalation of subcutaneous infliximab after loss of response, and characterized patients who experienced early recovery. Methods: This analysis included week 10 responders to intravenous infliximab induction who were randomized to receive subcutaneous infliximab 120 mg every other week (Q2W) and underwent dose escalation to 240 mg Q2W following loss of response. Time to response recovery was assessed, and outcomes pre-/post-dose escalation were analyzed by recovery timing (early [≤8 weeks], late [>8 weeks], non-recovery). Week 102 outcomes and factors associated with early recovery were evaluated. Results: Response recovery was achieved in 85.1% (40/47) with CD and 82.3% (51/62) with UC, with early recovery in 66.0% (31/47) and 69.4% (43/62), respectively. Early recovery groups in CD and UC showed greater serum infliximab increases than late or non-recovery groups. At week 102, numerically higher rates of clinical response and clinical remission in CD, and endoscopic remission in UC, were observed in early versus late recovery group. Factors associated with early recovery differed between CD and UC: systemic inflammatory and pharmacokinetic parameters were linked to early recovery in CD, while mucosal and gut-specific factors predominated in UC. Conclusion: Dose escalation of subcutaneous infliximab led to rapid response recovery in most patients with CD and UC. Early recovery was associated with favorable long-term outcomes. Clinical trial registration numbers: NCT03945019 and NCT04205643.
- 18 March 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (7) , 1235-1247
Open AccessRecovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials
Background: Rapidity of onset of efficacy following dose escalation of subcutaneous infliximab after loss of response remains unclear in Crohn’s disease (CD) and ulcerative colitis (UC). This post hoc analysis of the LIBERTY-CD and LIBERTY-UC trials evaluated time to response recovery following dose escalation of subcutaneous infliximab after loss of response, and characterized patients who experienced early recovery. Methods: This analysis included week 10 responders to intravenous infliximab induction who were randomized to receive subcutaneous infliximab 120 mg every other week (Q2W) and underwent dose escalation to 240 mg Q2W following loss of response. Time to response recovery was assessed, and outcomes pre-/post-dose escalation were analyzed by recovery timing (early [≤8 weeks], late [>8 weeks], non-recovery). Week 102 outcomes and factors associated with early recovery were evaluated. Results: Response recovery was achieved in 85.1% (40/47) with CD and 82.3% (51/62) with UC, with early recovery in 66.0% (31/47) and 69.4% (43/62), respectively. Early recovery groups in CD and UC showed greater serum infliximab increases than late or non-recovery groups. At week 102, numerically higher rates of clinical response and clinical remission in CD, and endoscopic remission in UC, were observed in early versus late recovery group. Factors associated with early recovery differed between CD and UC: systemic inflammatory and pharmacokinetic parameters were linked to early recovery in CD, while mucosal and gut-specific factors predominated in UC. Conclusion: Dose escalation of subcutaneous infliximab led to rapid response recovery in most patients with CD and UC. Early recovery was associated with favorable long-term outcomes. Clinical trial registration numbers: NCT03945019 and NCT04205643.
- Open Access
- 28 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Involving end-users in the design of a digital opioid safety intervention for adolescents and young adults (AYA) with inflammatory bowel diseases (IBD): A qualitative analysis of patient and clinician perspectives (Preprint)
BACKGROUND Chronic opioid use, a key predictor of opioid overdose, is common among adolescents and young adults (AYA) with inflammatory bowel diseases (IBD), underscoring a need for tailored interventions to monitor opioid exposure and risk for opioid-related harm. Prior research also highlights the need to engage both AYA IBD patients and IBD-focused clinicians in development of pain management and opioid safety interventions. Human-centered design (HCD) offers a promising approach to address this gap by directly engaging patients and clinicians in co-creating solutions. OBJECTIVE As a foundational effort, we leveraged HCD to identify and define AYA patient and clinician perspectives to inform the design and development of a digital opioid safety intervention. METHODS We conducted semi-structured interviews with AYA IBD patients and IBD-focused clinicians (gastroenterologists, surgeons, and nurses). Interviews explored patient experiences with pain management, opioid use, and transitions to adult care, as well as clinician experiences in monitoring pain and prescribing opioids. A co-design workshop, following the interviews, brought patient and clinician participants together to reflect as a group on the unique challenges of managing pain in IBD care and consider potential creative solutions to enhance pain management safety. Data were audio recorded, transcribed, and thematically analyzed using an inductive approach to identify themes. RESULTS A total of 17 participants (four AYA patients and 13 clinicians) contributed to the study. Thematic analysis generated three domains of needs that an opioid safety intervention should address: (1) Intersecting Needs (i.e. relevant at the patient and clinician and/or health system levels), (2) Patient-Level Needs (i.e. relevant at the patient level only), and (3) Clinician- and Health System-Level Needs (i.e. relevant at the clinician and/or health system levels only). Intersecting needs included integrating opioid safety interventions into multidisciplinary chronic care, supporting AYA transitions to independence, and acknowledging individual patient differences. Patient-level needs included assessing lived experiences of pain routinely, setting clear expectations about pain management, and connecting patients with safe non-opioid alternatives. Clinician- and system-level needs included accounting for pain management received outside the IBD clinic; addressing gaps in information, education, and resources regarding opioid risk or pain management; and coordinating safety efforts across clinical teams. CONCLUSIONS AYA patients with IBD and IBD-focused clinicians identified multiple needs, including integrating routine pain assessments, connecting patients with safe pain management strategies, and facilitating smooth AYA transitions to adult care. Incorporating these insights into the development of a digital opioid safety intervention may enhance alignment between patient and clinician expectations regarding safe pain management and opioid use. This study underscores the value of HCD in developing digital opioid safety tools that are practical, patient-focused, and effectively integrated into clinical workflows. Findings can guide future intervention design, prototyping, and testing with continued engagement of AYA IBD patients and clinicians.
- 28 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessInvolving end-users in the design of a digital opioid safety intervention for adolescents and young adults (AYA) with inflammatory bowel diseases (IBD): A qualitative analysis of patient and clinician perspectives (Preprint)
BACKGROUND Chronic opioid use, a key predictor of opioid overdose, is common among adolescents and young adults (AYA) with inflammatory bowel diseases (IBD), underscoring a need for tailored interventions to monitor opioid exposure and risk for opioid-related harm. Prior research also highlights the need to engage both AYA IBD patients and IBD-focused clinicians in development of pain management and opioid safety interventions. Human-centered design (HCD) offers a promising approach to address this gap by directly engaging patients and clinicians in co-creating solutions. OBJECTIVE As a foundational effort, we leveraged HCD to identify and define AYA patient and clinician perspectives to inform the design and development of a digital opioid safety intervention. METHODS We conducted semi-structured interviews with AYA IBD patients and IBD-focused clinicians (gastroenterologists, surgeons, and nurses). Interviews explored patient experiences with pain management, opioid use, and transitions to adult care, as well as clinician experiences in monitoring pain and prescribing opioids. A co-design workshop, following the interviews, brought patient and clinician participants together to reflect as a group on the unique challenges of managing pain in IBD care and consider potential creative solutions to enhance pain management safety. Data were audio recorded, transcribed, and thematically analyzed using an inductive approach to identify themes. RESULTS A total of 17 participants (four AYA patients and 13 clinicians) contributed to the study. Thematic analysis generated three domains of needs that an opioid safety intervention should address: (1) Intersecting Needs (i.e. relevant at the patient and clinician and/or health system levels), (2) Patient-Level Needs (i.e. relevant at the patient level only), and (3) Clinician- and Health System-Level Needs (i.e. relevant at the clinician and/or health system levels only). Intersecting needs included integrating opioid safety interventions into multidisciplinary chronic care, supporting AYA transitions to independence, and acknowledging individual patient differences. Patient-level needs included assessing lived experiences of pain routinely, setting clear expectations about pain management, and connecting patients with safe non-opioid alternatives. Clinician- and system-level needs included accounting for pain management received outside the IBD clinic; addressing gaps in information, education, and resources regarding opioid risk or pain management; and coordinating safety efforts across clinical teams. CONCLUSIONS AYA patients with IBD and IBD-focused clinicians identified multiple needs, including integrating routine pain assessments, connecting patients with safe pain management strategies, and facilitating smooth AYA transitions to adult care. Incorporating these insights into the development of a digital opioid safety intervention may enhance alignment between patient and clinician expectations regarding safe pain management and opioid use. This study underscores the value of HCD in developing digital opioid safety tools that are practical, patient-focused, and effectively integrated into clinical workflows. Findings can guide future intervention design, prototyping, and testing with continued engagement of AYA IBD patients and clinicians.
- Open Access
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1016-1033
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis
Introduction While the therapeutic options for Crohn’s disease (CD) have broadened swiftly, direct comparative evidence on treatment efficacy remains limited. This study explored the relative efficacy and safety of available treatments based on current evidence. Methods A network meta-analysis (frequentist random-effect model) evaluated comparative efficacy of licensed advanced therapies for CD using data on efficacy of maintenance therapy from fully published, randomised, controlled phase 3/3b studies with 48–64-week follow-up periods and placebo or active comparator controls, identified through a systematic literature review (PROSPERO number CRD42023413752). Intravenous (IV) and subcutaneous (SC) infliximab, SC adalimumab, IV and SC vedolizumab, SC ustekinumab, SC risankizumab, and oral upadacitinib were included. Clinical remission and endoscopic response rates attained through maintenance regimens were assessed according to line of use (e.g., first-line and second-or-later line). Safety (serious adverse event rates) was also compared. Results Data from nine randomised controlled trials were analysed. SC infliximab 120 mg every 2 weeks (q.2.w.) exhibited the highest risk difference (95% confidence interval) vs. placebo in both first-line and second-or-later-line maintenance treatment for achieving clinical remission (0.38 [0.23–0.53] and 0.51 [0.19–0.83], respectively; 14 and 12 comparator arms, respectively), and endoscopic response (0.39 [0.29–0.49] and 0.35 [0.07–0.63], respectively; 5 comparator arms) compared with other treatments. Differences between therapies did not reach statistical difference. Safety was comparable among treatments in terms of rates of serious adverse events. Conclusions The current NMA integrating recently updated phase 3 data in CD indicated that no single treatment significantly outperformed others in achieving clinical remission and endoscopic response, although SC infliximab 120 mg q.2.w exhibited highest numerical efficacy as both a first-line and second-or-later-line maintenance treatment in adult patients with moderate-to-severe CD.
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1016-1033
Open AccessComparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis
Introduction While the therapeutic options for Crohn’s disease (CD) have broadened swiftly, direct comparative evidence on treatment efficacy remains limited. This study explored the relative efficacy and safety of available treatments based on current evidence. Methods A network meta-analysis (frequentist random-effect model) evaluated comparative efficacy of licensed advanced therapies for CD using data on efficacy of maintenance therapy from fully published, randomised, controlled phase 3/3b studies with 48–64-week follow-up periods and placebo or active comparator controls, identified through a systematic literature review (PROSPERO number CRD42023413752). Intravenous (IV) and subcutaneous (SC) infliximab, SC adalimumab, IV and SC vedolizumab, SC ustekinumab, SC risankizumab, and oral upadacitinib were included. Clinical remission and endoscopic response rates attained through maintenance regimens were assessed according to line of use (e.g., first-line and second-or-later line). Safety (serious adverse event rates) was also compared. Results Data from nine randomised controlled trials were analysed. SC infliximab 120 mg every 2 weeks (q.2.w.) exhibited the highest risk difference (95% confidence interval) vs. placebo in both first-line and second-or-later-line maintenance treatment for achieving clinical remission (0.38 [0.23–0.53] and 0.51 [0.19–0.83], respectively; 14 and 12 comparator arms, respectively), and endoscopic response (0.39 [0.29–0.49] and 0.35 [0.07–0.63], respectively; 5 comparator arms) compared with other treatments. Differences between therapies did not reach statistical difference. Safety was comparable among treatments in terms of rates of serious adverse events. Conclusions The current NMA integrating recently updated phase 3 data in CD indicated that no single treatment significantly outperformed others in achieving clinical remission and endoscopic response, although SC infliximab 120 mg q.2.w exhibited highest numerical efficacy as both a first-line and second-or-later-line maintenance treatment in adult patients with moderate-to-severe CD.
- Open Access
- 22 November 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (4) , 1111-1120
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study
- 22 November 2025
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (4) , 1111-1120
Open AccessEndoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study